Aspirin therapy is safe in cancer patients with ACS and thrombocytopenia
This article has no abstract so we have provided the first paragraph of the full text.
The benefits of aspirin therapy in patients with acute coronary syndromes (ACS) have been well documented. AHA/ACC guidelines recommend aspirin in all cases of ACS; however, it has been suggested that the bleeding risks associated with aspirin might outweigh the benefits of this therapy in patients with thrombocytopenia. Sarkiss et al. have evaluated aspirin therapy in cancer patients with ACS and thrombocytopenia secondary to chemotherapy or bone marrow suppression.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
